Temarotene
Modify Date: 2024-01-11 11:41:28
Temarotene structure
|
Common Name | Temarotene | ||
|---|---|---|---|---|
| CAS Number | 75078-91-0 | Molecular Weight | 304.46800 | |
| Density | 0.963g/cm3 | Boiling Point | 403.3ºC at 760 mmHg | |
| Molecular Formula | C23H28 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 218ºC | |
Use of TemaroteneTemarotene is an orally administered, particular arotinoid. |
| Name | Temarotene |
|---|---|
| Synonym | More Synonyms |
| Description | Temarotene is an orally administered, particular arotinoid. |
|---|---|
| Related Catalog | |
| In Vitro | Modulation of ornithine decarboxylase (ODC) gene expression by retinoids is analyzed in human keratinocyte cultures maintained in serum-free medium containing 0.15 mM Ca2+. Cells are incubated with all-trans-retinoic acid, 13-cis-retinoic acid or arotinoid Ro15-0778 (0.1 nM to 10 μM), total RNA is isolated, and mRNA transcripts for ODC are analyzed by Northern and slot blot hybridizations with a human ODC cDNA. Treatment of cells for 24 h results in a dose-dependent decrease in ODC mRNA levels, with an estimated IC50 of approximately 10 nM for all-trans- and 13-cis-retinoic acid, while Ro15-0778 is somewhat less effective (IC50 approximately 0.1-0.5 μM). The suppression of ODC mRNA levels by retinoids is detectable at approximately 3 h of incubation, with essentially a maximal inhibition at 12 h. Reduced ODC mRNA levels noted after 24 h of incubation with 0.5 μM all-trans-retinoic acid are accompanied by a reduction in ODC enzyme activity[1]. |
| In Vivo | The aim of this preliminary report is to measure plasma and skin concentrations of Ro 15-0778 and its phenolic metabolite Ro 14-6113 in hairless rats receiving orally 10 mg/kg of Temarotene once daily during 10 days. Blood (2-3 mL) and skin (200-300 mg) samples are taken at different time points between 0.5 and 240 h after the last dose. A highly sensitive HPLC method is used for simultaneous determination of the two compounds with a quantification limit of 2 ng/mL in plasma and 10 ng/g in total skin (epidermis and dermis). After 10 h, plasma concentrations of Ro 14-6113 are 5-13 times higher than for Ro 15-0778. Ro 14-6113 concentrations in the skin are 4-10 times higher than for Ro 15-0778 within the initial 48 h. The concentrations of both compounds in the skin are higher than concentrations in plasma[1]. |
| References |
| Density | 0.963g/cm3 |
|---|---|
| Boiling Point | 403.3ºC at 760 mmHg |
| Molecular Formula | C23H28 |
| Molecular Weight | 304.46800 |
| Flash Point | 218ºC |
| Exact Mass | 304.21900 |
| LogP | 6.59610 |
| Index of Refraction | 1.56 |
| Storage condition | 2-8℃ |
CAS#:38111-44-3
CAS#:83832-05-7
CAS#:27452-17-1
CAS#:100-52-7![[1-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-ethyl]-triphenylphosphonium bromide Structure](https://www.chemsrc.com/caspic/018/69251-24-7.png)
CAS#:69251-24-7
CAS#:17610-21-8
CAS#:69251-25-8
CAS#:18826-59-0| AROTINOID |
| Temaroteno |
| Ro-15-0778 |
| Naphthalene,1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-((1E)-1-methyl-2-phenylethenyl) |
| Temaroteno [spanish] |
| p-<(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-propenyl>-benzene |
| (E)-1,1,4,4-tetramethyl-6-(1-phenylprop-1-en-2-yl)-1,2,3,4-tetrahydronaphthalene |
| (E)-1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-(1-methyl-2-phenylethenyl)-naphthalene |
| Temarotenum |
| Naphthalene,1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-(1-methyl-2-phenylethenyl)-,(E) |
| 1,2,3,4-Tetrahydro-1,1,4,4-tetramethyl-6-[(E)-1-methyl-2-phenylethenyl]naphthalene |
| 4-[(1E)-2-(5,5,8,8-tetramethyl-5,6,7,8 tetrahydro-2-naphthalenyl)]-1-phenyl-1-propene |